NCT02090530Recruiting
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Ohio State University Comprehensive Cancer Center
Start Date
11/4/2013
Completion Date
12/31/2027
Summary
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Detailed Description
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
1. A histologically or cytologically confirmed diagnosis of cancer
2. Patients with any malignancy.
3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.
OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes.
4. Procedure-specific signed informed consent prior to initiation of any study-related procedures.
5. Women and minorities are included in this protocol.
6. Patients with multiple malignancies remain eligible.
7. Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.
Exclusion Criteria:
1. It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
2. Patients who are incarcerated are not eligible to participate.
Interventions
OTHER
Biospecimen collection
Conditions
Cancer
Locations
Ohio State University Wexner Medical Center
Columbus, Ohio 43210
United States